Cck Positive Interneurons is an important cell type in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
CCK+ interneurons are a major class of cortical GABAergic neurons characterized by cholecystokinin expression. These neurons represent approximately 25-30% of cortical interneurons and play crucial roles in regulating pyramidal neuron excitability, network oscillations, and cognitive function [1].
Cholecystokinin-positive (CCK+) interneurons are among the most abundant interneuron populations in the cerebral cortex and hippocampus. Unlike parvalbumin (PV+) basket cells, CCK+ basket cells preferentially target the soma and proximal dendrites of pyramidal neurons, providing powerful perisomatic inhibition. CCK+ interneurons are distinguished by their expression of the neuropeptide cholecystokinin and the cannabinoid receptor type 1 (CB1), which mediates activity-dependent modulation of inhibition [2].
CCK+ interneurons exhibit diverse morphological subtypes:
- CCK+ basket cells: Characterized by dense axonal arborizations forming perisomatic baskets around pyramidal neuron somata. The axon initial segment is a primary target.
- Dendrite-targeting interneurons: Axons preferentially target distal dendrites of pyramidal neurons and interneurons
- Axo-axonic cells: Some CCK+ neurons target axon initial segments (less common than PV+ axo-axonic cells)
- Bipolar/bitufted cells: Elongated dendritic trees spanning cortical layers
CCK+ interneurons receive diverse inputs:
- Local pyramidal neurons: Excitatory feedback
- Other interneurons: Cross-inhibition
- Thalamocortical afferents: Sensory input integration
- Subcortical modulators: Cholinergic, serotonergic inputs
- CCK: Cholecystokinin peptide (primary defining marker)
- CNR1 (CB1): Cannabinoid receptor type 1 - highest expression in brain [3]
- GAD1/GAD2: GABA synthesis enzymes
- VGLUT3: Vesicular glutamate transporter (co-release glutamate)
CCK+ neurons often co-express:
- PV (PVALB): Can be co-expressed in some subpopulations
- CR (CALB2): Calretinin in subset
- VIP: Vasoactive intestinal peptide (partial overlap)
- nNOS: Neuronal nitric oxide synthase (subset)
- Reelin (RELN): Some CCK+ basket cells
- Lhx6: Required for CCK+ interneuron development
- Npas1: CCK+ interneuron specification
- Satb1: Chromatin regulator in CCK+ development
CCK+ interneurons display characteristic firing properties:
- Regular-spiking: Moderate firing rates
- Adapting spike trains: Frequency adaptation during sustained depolarization
- Low-threshold spiking: In some subtypes
- Fast-spiking subset: Some CCK+ basket cells approach fast-spiking characteristics
- Resting membrane potential: -65 to -70 mV
- Input resistance: 150-300 MΩ
- Membrane time constant: 10-20 ms
- Action potential duration: 0.5-1.0 ms
CCK+ basket cells provide powerful inhibition at the soma [4]:
- Timing control: Precisely timed inhibition regulates pyramidal neuron spike timing
- Gain modulation: Control input-output functions
- Synchronization: Coordinate pyramidal neuron firing ensembles
- Feedback inhibition: Respond to elevated excitatory activity
CCK+ interneurons contribute to cortical oscillations:
- Gamma oscillations (30-80 Hz): CCK+ basket cells drive gamma through perisomatic inhibition
- Theta oscillations (4-8 Hz): Phase coupling with hippocampal interneurons
- Sharp wave-ripples: CCK+ cell activity during replay events
The CB1 receptor provides unique modulation [5]:
- Depolarization-induced suppression of inhibition (DSI): Endocannabinoid release reduces CCK+ release
- Activity-dependent plasticity: CB1 enables flexible circuit modulation
- ** retrograde signaling**: Postsynaptic activity triggers presynaptic modulation
- Homeostatic regulation: Maintains excitation-inhibition balance
CCK+ interneuron alterations in AD [6]:
- CCK level changes: Decreased CCK in cortex and hippocampus
- Circuit dysfunction: Loss of perisomatic inhibition
- Gamma oscillation deficits: Impaired gamma rhythms correlate with memory impairment
- CB1 receptor changes: Altered endocannabinoid signaling
- Early vulnerability: CCK+ neurons may show early deficits
- CCK receptor alterations: Changed CCK receptor density in prefrontal cortex
- Gamma band deficits: Impaired gamma oscillations linked to working memory deficits
- Perisomatic inhibition: Altered inhibition affecting pyramidal neuron function
- Genetic associations: CCK gene polymorphisms linked to schizophrenia risk
- CCK+ cell loss: Selective loss in temporal lobe epilepsy
- Inhibition imbalance: Reduced perisomatic control
- Hyperexcitability: Failure to suppress seizure-like activity
- CB1 alterations: Changed cannabinoid modulation in epileptic tissue
- CCK signaling: Altered CCK and receptor expression
- Circuit-specific deficits: Imbalanced excitation/inhibition
- Social cognition: CCK's role in social behavior processing
Cholecystokinin acts through CCK receptors [7]:
- CCK1 receptors: Peripherally expressed, some CNS expression
- CCK2 receptors: Primary CNS receptor
- G-protein coupling: Activate phospholipase C pathway
- Intracellular effects: Increase intracellular Ca²⁺, activate PKC
CB1 receptor mechanisms:
- Endocannabinoids: Anandamide (AEA), 2-arachidonoylglycerol (2-AG)
- Presynaptic inhibition: Reduce GABA release probability
- Activity-dependent: Locally released during high activity
- Metabolic enzymes: FAAH, MAGL for degradation
Potential therapeutic approaches:
- CCK agonists: Enhance CCK signaling for cognitive enhancement
- CB1 modulators: Strategic modulation of endocannabinoid signaling
- Gamma oscillation enhancers: Restore gamma rhythms
- Circuit-specific interventions: Targeted manipulation of CCK+ networks
- Biomarker potential: CCK levels as disease progression markers
- Treatment targets: CCK receptor drugs in development
- Cognitive enhancement: CCK's role in memory consolidation
The study of Cck Positive Interneurons has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
-
Kawaguchi Y, et al. (1995). "Physiological diversity of neocortical interneurons." Cerebral Cortex
-
Freund TF, et al. (1990). "Cholecystokinin-containing interneurons." Neuroscience Letters
-
Herkenham M, et al. (1990). "Cannabinoid receptor localization in brain." Proceedings of the National Academy of Sciences
-
Cobb SR, et al. (1999). "Synaptic connections of cholecystokinin basket cells." Neuroscience Letters
-
Wilson RI, et al. (2001). "Endocannabinoid signaling in the hippocampus." Neuron
-
[Gulyás AI, et al. (2010). "CCK interneurons in Alzheimer's disease." Cerebral Cortex(https://pubmed.ncbi.nlm.nih.gov/20083556/)
-
[Moran TH, et al. (1990). "CCK receptors and brain function." Neuropeptides(https://pubmed.ncbi.nlm.nih.gov/1978749/)